SCHEMBL992986

SCHEMBL992986

Clc1cc(-c2c[nH]c3ncccc23)cc(NCC2CCOCC2)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 18/20 0.64
ROCK2 O75116 17/20 0.64
PRKACA P17612 17/20 0.64
CDK2 P24941 16/20 0.64
HIPK2 Q9H2X6 16/20 0.64
GSK3B P49841 15/20 0.64
PIM1 P11309 15/20 0.64
MAP4K4 O95819 12/20 0.64
CLK4 Q9HAZ1 12/20 0.64
DYRK1A Q13627 11/20 0.64
CDK7 P50613 10/20 0.64
CDK9 P50750 10/20 0.64
MELK Q14680 9/20 0.64
STK17A Q9UEE5 9/20 0.64
CLK2 P49760 9/20 0.64
CDK5 Q00535 9/20 0.64
IRAK4 Q9NWZ3 8/20 0.64
DAPK3 O43293 8/20 0.64
PRKX P51817 8/20 0.64
PKN2 Q16513 8/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1045527 0.89 CDC7 (0.60) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1043893 0.85 CDC7 (0.63) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1044364 0.85 CDC7 (0.81) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL992827 0.85 CDC7 (0.62) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL992787 0.84 CDC7 (0.61) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL992125 0.84 CDC7 (0.64) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL6123106 0.84 CDC7 (0.61) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1044968 0.84 CDC7 (0.61) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1046852 0.82 CDC7 (0.59) CDC7ROCK2PRKACACDK2HIPK2
SCHEMBL1045370 0.82 CDC7 (0.58) CDC7ROCK2PRKACACDK2HIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP claimed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US claimed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP claimed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO claimed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US claimed
EP-2454257-B1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBVIE INC (US) 2013-08-21 EP disclosed
US-8435980-B2 Pyrrolopyridine inhibitors of kinases ABBVIE INC. (US) 2013-05-07 US disclosed
EP-2454257-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES Abbott Laboratories (US) 2012-05-23 EP disclosed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO disclosed
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015173-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES CDC7, MAP3K7, CDK1 CDC7 1/4885ROCK2 373/4885PRKACA 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.